3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole | 1213236-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole
• 英文别名: 3-Methyl-1-[4-(trifluoromethyl)phenyl]indazole
• CAS: 1213236-31-7
• 化学式: C₁₅H₁₁F₃N₂
• 分子量: 276.261
• InChiKey: FCQCEQXABBRJOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-1-(2-(4-(trifluoromethyl)phenylamino)phenyl)ethanone oxime 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以80%的产率得到3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-indazole
  参考文献：
  名称：

  通过Mitsunobu反应从邻氨基苯并肟中构建1 H-吲唑

  摘要：

  近来，在药物发现中吲唑基序的出现已经激增。因此，文献中出现了更新，更温和和更有效的合成途径。最近，我们报道了水延醛肟的Mitsunobu引发的环脱水反应，以生成瞬态1,2-苯并恶唑，水杨基异羟肟酸触发了其相应的3-羟基苯并恶唑。我们假设使邻氨基苯甲酸酯经受Mitsunobu条件同样会引起环脱水作用，从而释放出相应的1 H-吲唑。实际上，仲苯胺提供了预期的N 1-取代的1 H-吲唑，而伯苯胺在被Boc基团激活后提供了N 1-Boc 1 H-吲唑的收率良好至极佳。这项工作进一步扩大了Mitsunobu反应的化学组成，代表了其在1 H-吲唑核结构中的空前应用。

  DOI：

  10.1016/j.tetlet.2019.07.020

文献信息

• METHOD OF SYNTHESIZING 1H-INDAZOLE COMPOUNDS
  申请人：Stambuli James P.

  公开号：US20100056800A1

  公开（公告）日：2010-03-04

  A method is provided for synthesizing 1H-indazole compounds in which aromatic carbonyl compounds are reacted with a nitrogen source to form oximes which are then converted to 1H-indazoles.

  提供了一种合成1H-吲唑化合物的方法，其中芳香酮化合物与氮源反应形成肟类，然后转化为1H-吲唑。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Exploring Synthetic Strategies for 1<i>H</i>‐Indazoles and Their <i>N</i>‐Oxides: Electrochemical Synthesis of 1<i>H</i>‐Indazole <i>N</i>‐Oxides and Their Divergent C−H Functionalizations
  作者：Sagar Arepally、Taehoon Kim、Gyeongho Kim、Haesik Yang、Jin Kyoon Park

  DOI：10.1002/anie.202303460

  日期：2023.6.26

  The study reports selective electrochemical synthesis of 1H-indazoles and N-oxides, where electrochemical outcomes were dictated by the cathode material (RVC=reticulated vitreous carbon). The adaptability of 1H-indazole N-oxides for various C−H functionalization reactions was showcased. Furthermore, 1H-indazole N-oxides were utilized to synthesize the pharmaceutical molecules lificiguat and YD (3)

  该研究报告了 1 H-吲唑和N-氧化物的选择性电化学合成，其中电化学结果由阴极材料决定（RVC=网状玻璃碳）。展示了1 H -吲唑N -氧化物对各种 C−H 官能化反应的适应性。此外，1 H -吲唑N -氧化物被用于合成药物分子 lificiguat 和 YD (3)，各种药物的关键中间体，以及有机发光二极管的前体。
• Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1935887A1

  公开（公告）日：2008-06-25

  The invention relates to heterocyclic substituted carbonyl derivatives of the formula I that display selective binding to dopamine D3 receptors and are useful for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

  本发明涉及式 I 的杂环取代的羰基衍生物 本发明涉及式 I 的杂环取代羰基衍生物，该衍生物与多巴胺 D3 受体具有选择性结合，可用于治疗需要此类治疗的患者中与多巴胺 D3 受体活性相关的中枢神经系统紊乱，包括向受试者施用治疗有效量的所述化合物以缓解此类紊乱。可用这些化合物治疗的中枢神经系统疾病包括精神障碍、药物依赖、药物滥用、运动障碍（如帕金森病、帕金森氏症、神经抑制剂诱发的迟发性运动障碍、吉勒-德拉图雷特综合征和亨廷顿氏病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及本文所述化合物的制备过程以及将这些化合物用作多巴胺 D3 受体成像剂的制备和使用方法。